Eisai Exits Dermatology Through Roivant Deal
This article was originally published in PharmAsia News
Eisai has followed in the footsteps of Japanese peer Astellas by divesting assets in the dermatology area, this time through a deal with Roivant for a clinical stage atopic dermatitis therapy that it sees as no longer fitting into its strategic priorities.
You may also be interested in...
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
In this week's podcast edition of Five Must-Know Things: a slow start for Biogen’s Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.
Results from a large Swedish study provide further evidence that mixing different COVID-19 vaccines boosts effectiveness. Meanwhile, Japan plans new funding to support the home-grown development of coronavirus and other vaccines.